Skip to main content
Fig. 16 | BMC Cancer

Fig. 16

From: Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer

Fig. 16

Forest Plot of Discontinuation Due to AEs: Safety Analysis. Estimates derived only from indirect comparisons shown in black box. Included references: Study 301 (Kaufman 2015, Pivot 2018), EMBRACE (Cortes 2011), CA163–046 (Thomas 2007; Rugo 2018), Pallis 2012, Vahdat 2013, Zhang 2017. Abbreviations: AE = adverse event; CAP = capecitabine; CrI = credible interval; ERI = eribulin; GEM = gemcitabine; IXA = ixabepilone; TPC = treatment by physician’s choice; UTI = utidelone; VIN = vinorelbine

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us